Takamatsu J, Horne M K, Gralnick H R
J Clin Invest. 1986 Feb;77(2):362-8. doi: 10.1172/JCI112313.
To identify the molecular site of thrombin binding to the platelet membrane, we covalently linked 125I-thrombin to platelets by using the bifunctional chemical cross-linking agents disuccinimidyl suberate and dithiobis(succinimidyl propionate). The proteins cross-linked to 125I-thrombin by this method were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and followed by autoradiography. Two radiolabeled thrombin complexes were identified, a major species of Mr approximately 200,000 and a minor one of Mr approximately 400,000. Hirudin prevented the formation of both complexes. The radioactivity of the approximately 200,000-Mr complex was always 7-10-fold greater than the radioactivity of the approximately 400,000-Mr complex regardless of the thrombin concentration to which the platelets were exposed (0.1-29 nM). Although 125I-thrombin complexes generated with thrombasthenic platelets (lacking glycoprotein IIb/IIIa) were indistinguishable from normal, no complexes appeared when Bernard-Soulier platelets (lacking glycoprotein Ib [GPIb]) were used. Complex formation was blocked by rabbit antiglycocalicin antiserum, but not by the monoclonal antibody 6D1, which is directed against the site on GPIb where von Willebrand factor (vWf) binds in the presence of ristocetin. Although cross-linking studies suggested that vWf might partially inhibit thrombin binding to platelets, this was not confirmed by equilibrium binding studies in the presence of vWf and ristocetin. The data suggest, therefore, that at all thrombin concentrations binding occurs at the same membrane site, despite evidence from equilibrium studies for high and low affinity classes of receptors, and that the approximately 400,000-Mr complex is simply a dimer of the approximately 200,000-Mr species. We conclude that the membrane site to which thrombin binds is the glycocalicin portion of platelet GPIb at a site remote from the point of ristocetin-dependent vWf binding.
为了确定凝血酶与血小板膜结合的分子位点,我们使用双功能化学交联剂辛二酸二琥珀酰亚胺酯和二硫代双(琥珀酰亚胺丙酸酯)将¹²⁵I-凝血酶与血小板共价连接。通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳分析用此方法与¹²⁵I-凝血酶交联的蛋白质,随后进行放射自显影。鉴定出两种放射性标记的凝血酶复合物,一种主要的分子量约为200,000,另一种次要的分子量约为400,000。水蛭素可阻止两种复合物的形成。无论血小板暴露于何种凝血酶浓度(0.1 - 29 nM),约200,000分子量复合物的放射性总是比约400,000分子量复合物的放射性大7 - 10倍。尽管用血小板无力症血小板(缺乏糖蛋白IIb/IIIa)产生的¹²⁵I-凝血酶复合物与正常复合物无差异,但使用伯纳德-索利尔血小板(缺乏糖蛋白Ib [GPIb])时未出现复合物。复合物的形成被兔抗糖萼蛋白抗血清阻断,但未被单克隆抗体6D1阻断,单克隆抗体6D1针对的是在瑞斯托霉素存在下血管性血友病因子(vWf)结合的GPIb位点。虽然交联研究表明vWf可能部分抑制凝血酶与血小板的结合,但在vWf和瑞斯托霉素存在下的平衡结合研究未证实这一点。因此,数据表明,尽管平衡研究显示存在高亲和力和低亲和力受体类别,但在所有凝血酶浓度下,结合都发生在同一膜位点,并且约400,000分子量的复合物只是约200,000分子量物种的二聚体。我们得出结论,凝血酶结合的膜位点是血小板GPIb的糖萼蛋白部分,位于远离瑞斯托霉素依赖性vWf结合点的位点。